Anticoagulants Show a Protective Effect Against COVID-19

A new study published on a pre-print server investigated the association between the use of oral anticoagulants and warfarin in COVID-19 disease outcomes. A few studies have shown that using anticoagulants like heparin can reduce the risk of blood clots in patients who have been hospitalized due to COVID-19. Vitamin K levels have also been reported to be decreased in COVID-19, and a correlation has been seen between vitamin K levels and COVID-19 severity.

The study included 52,000 oral anticoagulant users with a median age of 71 years and about 18,000 non-users with a median age of 69 years. They found a lower risk of testing positive for SARS-CoV-2 and COVID-19-related hospitalization and death in oral anticoagulant users compared to non-users. The study also included about 92,000 warfarin users with a median age of 79 years and about 280,000 users of direct anticoagulants with a median age of 78 years. Statistical analysis indicated a lower risk of testing positive for SARS-CoV-2 and COVID-19-related hospitalization and death in warfarin users compared to direct anticoagulant users.

There is some evidence that direct Xa inhibitors (anticoagulants) may hinder the entry of SARS-CoV-2 by preventing the splitting of the spike protein into the S1 and S2 subunits. Still, there is no clinical evidence of the protective effects of oral anticoagulants. Also, the researchers found that anticoagulant or warfarin users were less likely to be smokers, excessive alcohol drinkers, and more likely to have taken flu shots compared to non-users or direct oral anticoagulant users.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link: https://www.medrxiv.org/content/10.1101/2021.04.30.21256119v1

#Featured